Premium
Delay of dimethylbenz[ a ]anthracene‐induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein
Author(s) -
Li Baolin,
Kittrell Frances S.,
Medina Daniel,
Rosen Jeffrey M.
Publication year - 1995
Publication title -
molecular carcinogenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.254
H-Index - 97
eISSN - 1098-2744
pISSN - 0899-1987
DOI - 10.1002/mc.2940140203
Subject(s) - dmba , biology , transgene , apoptosis , carcinogenesis , mutant , genetically modified mouse , 7,12 dimethylbenz[a]anthracene , cancer research , mammary gland , mammary tumor , wild type , endocrinology , microbiology and biotechnology , medicine , stimulation , gene , cancer , biochemistry , breast cancer , genetics
Murine p53 containing an Arg → Leu substitution at amino acid 172 possesses many properties characteristic of wild‐type p53, including the ability to induce p21/WAF/Cip1 and apoptosis. To determine if p53–dependent apoptosis plays a critical role in mammary tumorigenesis, transgenic mice were generated in which the expression of this mutant p53 protein was targeted to the mammary gland by using the rat whey acidic protein gene promoter. Mice bearing pituitary isografts were treated with 7,12–dimethylbenz[ a ]anthracene (a) and examined for mammary tumor development. Mice overexpressing the p53 transgene exhibited a statistically significant increase in apoptosis in the mammary gland and a statistically significant decrease in the incidence of DMBA‐induced mammary tumors. No difference in tumor incidence was observed in mice without pituitary isografts who were treated with DMBA, because the transgene is not overexpressed in the absence of hormone stimulation provided by the pituitary isograft. The unexpected wild‐type properties of the 172 Arg→Leu mutant p53 , including its ability to stimulate apoptosis, make it a possible candidate for use in gene therapy protocols. ©1995 Wiley‐Liss, Inc.